重症脑梗死患者的早期肠内营养支持的应用

目的:研究重症脑梗死患者早期应用肠内营养支持对机体营养指标及胃肠道功能的临床效果。方法:对确诊为重症脑梗死的患者62例,以抽签法随机分为治疗组与对照组,分别用改良与传统方法实施鼻饲。结果:治疗组患者治疗前后血清白蛋白、非瘫痪侧上臂三头肌肌围(moveablearmmuscularcirculation,MAMC)和三头肌皮褶厚度(tricepsskinfold,TSF)等营养指标值在14d与1d比较时有统计学意义(t=2.32～11.75,P<0.05),各营养指标变化值在14d时治疗组较对照组差异有显著性意义犤血清白蛋白:(33.3±2.5)比(29.5±2.3)g/L;TSF:(13.51±2.27)比(12.35±2.13)mm;MAMC:(21.35±2.43)比(18.89±1.78)cm犦(P<0.05)。治疗组的上消化道出血、呕吐反流、腹胀和拒食等胃肠胃功能障碍的发生率均显著低于对照组(P<0.05)。结论:早期肠内营养支持可减轻重症脑梗死患者的营养状况恶化程度,有助于胃肠道功能的改善。     

O Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.     

From expert-derived user needs to user-perceived ease of use and usefulness: A two-phase mixed-methods evaluation framework

Underspecified user needs and frequent lack of a gold standard reference are typical barriers to technology evaluation. To address this problem, this paper presents a two-phase evaluation framework involving usability experts (phase 1) and end-users (phase 2). In phase 1, a cross-system functionality alignment between expert-derived user needs and system functions was performed to inform the choice of “the best available” comparison system to enable a cognitive walkthrough in phase 1 and a comparative effectiveness evaluation in phase 2. During phase 2, five quantitative and qualitative evaluation methods are mixed to assess usability: time-motion analysis, software log, questionnaires – System Usability Scale and the Unified Theory of Acceptance of Use of Technology, think-aloud protocols, and unstructured interviews. Each method contributes data for a unique measure (e.g., time motion analysis contributes task-completion-time; software log contributes action transition frequency). The measures are triangulated to yield complementary insights regarding user-perceived ease-of-use, functionality integration, anxiety during use, and workflow impact. To illustrate its use, we applied this framework in a formative evaluation of a software called Integrated Model for Patient Care and Clinical Trials (IMPACT). We conclude that this mixed-methods evaluation framework enables an integrated assessment of user needs satisfaction and user-perceived usefulness and usability of a novel design. This evaluation framework effectively bridges the gap between co-evolving user needs and technology designs during iterative prototyping and is particularly useful when it is difficult for users to articulate their needs for technology support due to the lack of a baseline.     

Evaluation of circulating cell free DNA in plasma as a biomarker of different thyroid diseases

IntroductionMany studies have been done on proteomics, genomics, epigenetic, immunogenetics in many body fluids. Among these, circulating cell-free DNA (ccfDNA) entered the literature in 1948, but it has not been studied for many years due to technological deficiencies. Following recent advances, geno-metastasis has been mentioned and new research is needed in this area. ccfDNA is known to be an important biomolecule in this regard.ObjectiveThe presence of cell-free DNA in the circulatory system may offer a tremendous opportunity to provide novel biomarkers for thyroid diseases. This experimental study was conducted to determine the amount of ccfDNA in different thyroid diseases, then to evaluate whether the ccfDNA concentration varied between the disease groups and control group.MethodsIn total, we included 121 individuals in the present study. We collected blood samples and then determined the ccfDNA concentration in plasma of collected blood samples from three groups: thyroiditis (n = 33), benign (n = 37), and malignant (n = 30) and from a control group (n = 21).ResultsThe median values of the ccfDNA groups were found as 1610, 1665, 1685 and 576 ng/mL for the thyroiditis, benign, malign, and control groups, respectively. Findings showed that the ccfDNA of the three groups was significantly higher than the control (p < 0.0001). Each group was compared in terms of ccfDNA and the p-values of benign-thyroiditis, benign-malign, and thyroiditis-malign were 0.09, 0.65, and 0.29, respectively.ConclusionsThe clear differences between thyroid diseases and controls suggest that ccfDNA is worthy of attention as a biomarker for further evaluation of different thyroid diseases. Likewise, it might indicate a clear tendency that ccfDNA can also be used to distinguish different thyroid diseases.     

六味地黄滴心丸制备工艺的研究

目的:优选六味地黄滴心丸的制备工艺。方法:滴心丸的制备过程分二步:第一步以牡丹皮萃取物、泽泻萃取物为主药制成滴丸,通过单因素试验、正交试验,以多指标综合评分法优选制备条件。第二步以滴丸为母核,采取泛制方法,取混合好的六味地黄方药粉、辅料等包裹于滴丸母核上,成型,盖面,干燥,整丸,选丸,包衣,制成六味地黄滴心丸。结果:滴丸母核制备的最佳工艺条件为:主药与基质配比不得低于1∶2;基质应采用PEG10000与PEG6000混合的二种基质,比例为1∶10;冷凝液选择二甲基硅油,温度为10℃;滴头温度85℃;滴距5cm。泛制法制丸时最适宜的黏合剂为:甘油:95%乙醇=1∶9。结论:用该方法制备的六味地黄滴心丸,质量可控,方法可靠,易于崩解,可防止挥发性及脂溶性物质丢失,适合于含挥发性及脂溶性物质的中药复方的剂型制备。